Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of T-817MA in mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease
2018-003567-66Phase 2Completed
- Sponsor
- FUJIFILM Toyama Chemical
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease comparing T-817MA with Placebo (2 arms). Primary endpoint: Change in cerebrospinal fluid p-tau181 from baseline to Week 78. Started Dec 2018; status: completed.
02
Drugs
edonerpic
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on 2018-003567-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003567-66.